Cytochroma (Canada) a drug company focused on Psoriasis and chronic kidney disease raised Cnd$21M in Series C financing. Investors include VenGrowth Advanced Life Sciences Fund, Novo A/S and GeneChem Technologies Venture Fund.
Cytochroma, Inc.: Series C Cnd$21M
March 19, 2007
Leave a Comment » | 
I - Series C, R - INTERNATIONAL, X - Psoriasis | 
Permalink
Posted by arubenstein
